Bli medlem
Bli medlem

Du är här

2016-05-09

Photocure ASA: Positive clinical data on BLC with Cysview®/Hexvix® presented at AUA

Oslo, Norway, May 9, 2016 -- Photocure ASA announced today new data from a
prospective multicenter ongoing registry study that shows Blue Light
Cystoscopy (BLC) with Cysview®increases detection rates of flat, more
aggressive non-muscle invasive bladder cancer lesions (carcinoma in situ
(CIS)) as well papillary lesions over white light cystoscopy (WLC) alone. The
data from the prospective registry, real life, study including 175 patients,
was presented at the American Urological Association (AUA) annual meeting in
San Diego, CA, May 6-10, 2016.

The Blue Light Cystoscopy with Cysview®Registry was established to study the
use of BLC with Cysview®in clinical practice in the US in different patient
types.[i]The data presented at AUA included an analysis of 175 patients at
three major US urology and cancer centers between April 2014 and October
2015. A total of 548 separate lesions were identified from 220 BLC
procedures. The detection rate (sensitivity) of WLC, BLC and the combination
of WLC/ BLC for any malignant lesion was 73%, 91% and 98% respectively. The
addition of BL to standard WLC increased the detection rate by 12% in any
papillary lesions and 46% for CIS.[ii]

"This data further reinforces the critical role BLC with Cysview®plays in
advancing the care of bladder cancer patients," says Siamak Daneshmand, MD,
Associate Professor of Urology (Clinical Scholar) Director of Urologic
Oncology, University of Southern California Institute of Urology and study
investigator. "We know that BLC with Cysview®has clear benefits over white
light cystoscopy (WLC) alone in improving the detection and management of
patients with non-muscle invasive bladder cancer (NMIBC). That translates
into reduction in disease progression and recurrence. Therefore, I believe
that BLC with Cysview®should be considered a valuable tool for urologists."

"The registry will continue to add to the growing body of evidence of how BLC
with Cysview®can improve the detection and management of bladder cancer in
various patient populations," says Kjetil Hestdal, M.D., Ph.D., President and
CEO, Photocure ASA.

Additional data was also presented at AUA 2016. Please seeabstractfor more
information.

Blue Light Cystoscopy: The USC Experience

A separate series of case studies presented at AUA 2016 from the University of
Southern California (USC) demonstrated that the use of BLC with Cysview is a
useful tool for better detection of NMIBC including CIS in patients
undergoing TURBT for bladder cancer. BLC with Cysview was also useful in
detecting involvement of previous resection margins and finding obscured
ureteral orifices.[iii] Please seeabstractfor more information.

About Bladder Cancer

Bladder cancer is the fifth most commonly diagnosed cancer and is the fourth
most common cancer found in men in the US.[iv],[v],[vi]In 2016, it is
estimated that 76,960 new cases of bladder cancer will occur along with
16,390 deaths due to bladder cancer. Risk factors for bladder cancer include
advancing age, cigarette smoking, occupational exposure to dyes, tar, rubber
and solvent, chronic bladder irritation and infections, and prior diagnosis
of bladder cancer. Bladder cancer is one of the most expensive cancers to
manage, accounting for approximately $3.7 billion in direct costs each
year[vii],[viii].

Bladder cancer is classified into two types, non-muscle invasive bladder
cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the
depth of invasion in the bladder wall.[ix] NMIBC is still in contained the
inner layer of the bladder. These cancers are the most common (75%) of all BC
cases and include the stages Ta, carcinoma in situ (CIS) and T1 lesions. MIBC
signifies when cancer involving the deeper layers of the bladder wall. These
cancers, including stages T2, T3 and T4, are more likely to spread and are
more difficult to cure.[x]

About Photocure ASA

Photocure, headquartered in Oslo Norway, is a specialty pharmaceutical company
and world leader in photodynamic technology. Based on our unique proprietary
Photocure Technology®
platform. Photocure develops and commercializes highly selective and effective
solutions within disease areas with high unmet medical need, such as bladder
cancer, HPV and precancerous cervical lesions and skin conditions. Our aim is
to provide solutions which can improve health outcomes for patients
worldwide. Photocure is listed on the Oslo Stock Exchange (OSE: PHO).
Information about Photocure is available at www.photocure.com.

Cysview®
is tradename in U.S. and Canada,Hexvix®
in Europe

For more information, please contact:

Media Relations:

Amanda Merced
MCS Healthcare Public Relations
Tel: +1 908 234 9900
Email:amandam@mcspr.com
Company contacts:

Kjetil Hestdal
President and CEO
Tel: +47 913 19 535
Email:kh@photcure.no
Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000
Email:ed@photocure.no

Investor relations:

Trout International LLC
Lauren Williams
Tel: +44 20 3780 4972
Email:lwilliams@troutgroup.com

[i]Bazargani ST et al. Blue Light Cystoscopy for Diagnosis of Urothelial
Bladder Cancer: Results from a Prospective Multicenter Registry. Abstract
printed from AUA2016.org. April 5, 2016.
[ii]Bazargani ST et al. Blue Light Cystoscopy for Diagnosis of Urothelial
Bladder Cancer: Results from a Prospective Multicenter Registry. Abstract
printed from AUA2016.org. April 5, 2016.
[iii]Blue Light Cystoscopy: The USC Experience. Bazarganti ST, Djaladat H, et
al. Abstract printed from AUA2016.org. April 5, 2016.
[iv]SEER Cancer Statistics Factsheets: Bladder Cancer. National Cancer
Institute. Bethesda, MD. http://seer.cancer.gov/statfacts/html/urinb.html.
Accessed April 2016.
[v]Bladder Cancer. American Cancer Society.
http://www.cancer.org/acs/groups/cid/documents/webcontent/003085-pdf.pdf.
Accessed April 2016.
[vi]Hall M, Chang S, Dalbagni G et al. Guideline for the Management of
Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 Update. J
Urol. 2007;178(6):2314-2330.
[vii]Avritscher EB et al., Clinical model of lifetime cost of treating bladder
cancer and associated complications. Urology. 2006; 68:549-553.
[viii]Botteman et al. Clinical model of lifetime costs of treating bladder
cancer: a comprehensive review of the published literature.
Pharmacoeconomics. 2003; 21:315-1330.
[ix]Bladder Cancer. American Cancer Society.
http://www.cancer.org/acs/groups/cid/documents/webcontent/003085-pdf.pdf.
Accessed April 2016.
[x]Bladder Cancer. American Cancer Society.
http://www.cancer.org/acs/groups/cid/documents/webcontent/003085-pdf.pdf.
Accessed April 2016.

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Photocure ASA via Globenewswire

HUG#2010501

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.